Search

Stereotactic Synchrotron Radiotherapy (SSRT) and Microbeam Radiation Therapy (MRT) are both novel approaches to treat brain tumor and potentially other tumors using synchrotron radiation. Although the techniques differ by their principles, SSRT and MRT share certain common aspects with the possibility of combining their advantages in the future. For MRT, the technique uses highly collimated, quasi-parallel arrays of X-ray microbeams between 50 and 600 keV. Important features of highly brilliant Synchrotron sources are a very small beam divergence and an extremely high dose rate. The minimal beam divergence allows the insertion of so called Multi Slit Collimators (MSC) to produce spatially fractionated beams of typically ~25e75 micron-wide microplanar beams separated by wider (100e400 microns center-to-center(ctc)) spaces with a very sharp penumbra. Peak entrance doses of several hundreds of Gy are extremely well tolerated by normal tissues and at the same time provide a higher therapeutic index for various tumor models in rodents. The hypothesis of a selective radio-vulnerability of the tumor vasculature versus normal blood vessels by MRT was recently more solidified. SSRT (Synchrotron Stereotactic Radiotherapy) is based on a local drug uptake of high-Z elements in tumors followed by stereotactic irradiation with 80 keV photons to enhance the dose deposition only within the tumor. With SSRT already in its clinical trial stage at the ESRF, most medical physics problems are already solved and the implemented solutions are briefly described, while the medical physics aspects in MRT will be discussed in more detail in this paper. © 2015 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

International audience; Optical Computed Tomography (CT) is a promising technique for dosimetry of Microbeam Radiation Therapy (MRT), providing high resolution 3D dose maps. Here different MRT irradiation geometries are visualised showing the potential of Optical CT as a tool for future MRT trials. The Peak-to-Valley dose ratio (PVDR) is calculated to be 7 at a depth of 3mm in the radiochromic dosimeter PRESAGE (R). This is significantly lower than predicted values and possible reasons for this are discussed

High Intensity Focused ultrasound (HIFU) is a non-invasive cancer therapy that makes use of the mainly thermal effects of ultrasound to destroy tissue. In order to achieve reliable treatment planning, it is necessary to characterise the ultrasound source (transducer) and to understand how the wave propagates in tissue and the energy deposition in the focal region. This novel exploratory study investigated how HIFU affects PRESAGE®, an optical phantom used for radiotherapy dosimetry, which is potentially a rapid method of calibrating the transducer. Samples, of two different formulations, were exposed to focused ultrasound and imaged using Optical Computed Tomography. First results showed that, PRESAGE® changes colour on ultrasound exposure (darker green regions were observed) with the alterations being related to the acoustic power and sample composition. Future work will involve quantification of these alterations and understanding how to relate them to the mechanisms of action of HIFU.